Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 5/20 | 0.65 |
| ▸ | DRD5 | P21918 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.64 |
| ▸ | APLNR | P35414 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 1/20 | 0.64 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460269 | 0.99 | DRD1 (0.64) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| SCHEMBL13254785 | 0.81 | DRD1 (0.72) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL29797998 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL2916216 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL11107859 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL30628012 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL16187032 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL29431888 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL29424268 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Sch-23390 SCHEMBL5722114 | 0.79 | DRD1 (1.00) | DRD1DRD5CYP1A2CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058551-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 2000-12-13 | — | — | EP | claimed |
| WO-1999044615-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 1999-09-10 | — | — | WO | claimed |
| EP-2872145-B1 | FUSED BENZAZEPINES FOR TREATMENT OF TOURETTE'S SYNDROME | EMALEX BIOSCIENCES INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3919060-A1 | ECOPIPAM FOR TREATMENT OF TOURETTES SYNDROME | Emalex Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | EMALEX BIOSCIENCES INC (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3057595-B1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | EMALEX BIOSCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-9949983-B2 | Fused benzazepines for treatment of stuttering | PSYADON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals ,Inc. | 2016-09-22 | — | — | US | disclosed |
| EP-3057595-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | HORIZON TECHNOLOGY FINANCE CORPORATION | 2015-06-18 | — | — | US | disclosed |
| WO-2015058053-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | PSYADON PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2012033874-A1 | METHOD OF TREATING COMPULSIVE SELF-INJURIOUS BEHAVIORS | CHIPKIN RICHARD E (US) | 2012-03-15 | — | — | WO | disclosed |
| US-6410527-B1 | PSYCHOLOGICAL DISORDERS | SCHERING CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-20010025038-A1 | Administering to the mammal an effective amount of a D1/D5 (dopamine) antagonist or a D1/D5 partial agonist for reducing cravings of food or an addictive substance | COFFIN VICKI L (US) | 2001-09-27 | — | — | US | disclosed |
| US-6262049-B1 | REDUCING THE CRAVINGS OF A MAMMAL TO ANY DOPAMINE MEDIATED CRAVINGS INCLUDING FOOD OR ADDICTIVE SUBSTANCES. | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1058551-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999044615-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | TACR1, AVPR1A, AVPR1B | DRD1 28/4885DRD5 40/4885CYP1A2 704/4885 |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | COMT, SLC6A3, HTR5A | DRD1 40/4885DRD5 46/4885CYP1A2 599/4885 |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | COMT, SLC6A3, HTR3A | DRD1 30/4885DRD5 39/4885CYP1A2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.